ORIGINAL PAPER
Monitoring inflammation in patients diagnosed with non-small cell lung and colorectal cancer using blood levels of C-reactive protein, procalcitonin, and plasma gelsolin
1
Holy Cross Cancer Centre, Kielce, Poland
2
Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Bialystok, Bialystok, Poland
3
Independent Laboratory of Nanomedicine, Medical University of Bialystok, Bialystok, Poland
4
The Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland
5
The Department of Microbiology and Immunology, Jan Kochanowski University, Kielce, Poland
Submission date: 2023-03-17
Acceptance date: 2023-04-21
Publication date: 2023-06-30
Medical Studies 2023;39(2):103-113
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Plasma gelsolin (pGSN) was recently introduced as a new predictor of systemic inflammation outcomes, especially in critically ill patients. This study aimed to describe the potential interplay between C-reactive protein (CRP), procalcitonin (PCT), and pGSN concentrations in blood collected from patients diagnosed with colon and lung cancer and to assess their diagnostic potential when a combined evaluation of those 3 markers was performed.
Aim of the research:
We hypothesized that a correlation between increased blood levels of CRP and PCT and a decreased level of plasma gelsolin might help identify cancer-associated inflammatory responses and a higher risk of poor clinical outcomes.
Material and methods:
Blood samples collected from 159 subjects were subjected to the biochemical analysis of CRP and PCT, in addition to the assessment of pGSN levels using Western blotting.
Results:
Our results confirmed a significant increase in CRP and PCT concentrations in collected blood samples, while pGSN concentrations decreased. Because the values of the blood CRP, PCT, and pGSN concentration did not show a strong correlation within the tested groups, it might be assumed that the molecular and cell signalling background leading to changes in those markers differs.
Conclusions:
A better understanding of the clinical value of the simultaneous evaluation of CRP, PCT, and pGSN levels in patients suffering from rectal and lung cancer might help us identify those with inflammatory responses leading to poor clinical outcomes.
Plasma gelsolin (pGSN) was recently introduced as a new predictor of systemic inflammation outcomes, especially in critically ill patients. This study aimed to describe the potential interplay between C-reactive protein (CRP), procalcitonin (PCT), and pGSN concentrations in blood collected from patients diagnosed with colon and lung cancer and to assess their diagnostic potential when a combined evaluation of those 3 markers was performed.
Aim of the research:
We hypothesized that a correlation between increased blood levels of CRP and PCT and a decreased level of plasma gelsolin might help identify cancer-associated inflammatory responses and a higher risk of poor clinical outcomes.
Material and methods:
Blood samples collected from 159 subjects were subjected to the biochemical analysis of CRP and PCT, in addition to the assessment of pGSN levels using Western blotting.
Results:
Our results confirmed a significant increase in CRP and PCT concentrations in collected blood samples, while pGSN concentrations decreased. Because the values of the blood CRP, PCT, and pGSN concentration did not show a strong correlation within the tested groups, it might be assumed that the molecular and cell signalling background leading to changes in those markers differs.
Conclusions:
A better understanding of the clinical value of the simultaneous evaluation of CRP, PCT, and pGSN levels in patients suffering from rectal and lung cancer might help us identify those with inflammatory responses leading to poor clinical outcomes.
REFERENCES (34)
1.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
3.
Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-2380.
4.
Ismail F, Mahmoud A, Abdelhaleem H, Mamdoh A, Geneidy M, Kamal E. Primary Sjogren’s syndrome and B-non-Hodgkin lymphoma: role of CD4+ T lymphocytopenia. Rheumatol Int 2013; 33: 1021-1025.
5.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
6.
Thirumala R, Ramaswamy M, Chawla S. Diagnosis and management of infectious complications in critically ill patients with cancer. Crit Care Clin 2010; 26: 59-91.
7.
Zembower TR. Epidemiology of infections in cancer patients. Cancer Treat Res 2014; 161: 43-89.
8.
Keramidaris D, Koronakis N, Lagoudianakis EE, Pappas A, Koukoutsis I, Chrysikos I, Karavitis G, Toutouzas K, Manouras A. Procalcitonin in patients with colorectal cancer. J BUON 2013; 18: 623-628.
9.
Vincenzi B, Fioroni I, Pantano F, Angeletti S, Dicuonzo G, Zoccoli A, Santini D, Tonini G. Procalcitonin as diagnostic marker of infection in solid tumors patients with fever. Sci Rep 2016; 6: 28090.
10.
Dumache R, Rogobete AF, Bedreag OH, Sarandan M, Cradigati AC, Papurica M, Dumbuleu CM, Nartita R, San- desc D. Use of miRNAs as biomarkers in sepsis. Anal Cell Pathol 2015; 2015: 186716.
11.
Liu HH, Guo JB, Geng Y, Su L. Procalcitonin: present and future. Ir J Med Sci 2015; 184: 597-605.
12.
Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res 2000; 49 Suppl 1: S57-61.
13.
Matzaraki V, Alexandraki KI, Venetsanou K, Piperi C, Myrianthefs P, Malamos N, Giannakakis T, Karatzas S, Diamanti-Kandarakis E, Baltopoulos G. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem 2007; 40: 336-342.
14.
Giovanella L, Suriano S, Ricci R, Ravani P, Ceriani L. Circulating procalcitonin in aseptic carcinoma patients: a specificity study with (18)F-fluorodeoxyglucose positron-emission tomography/computed tomography as benchmark. Clin Chem Lab Med 2010; 48: 1163-1165.
15.
Janmey PA, Stossel TP. Modulation of gelsolin function by phosphatidylinositol 4,5-bisphosphate. Nature 1987; 325: 362-364.
16.
Bucki R, Levental I, Kulakowska A, Janmey PA. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 2008; 9: 541-551.
17.
Osborn TM, Verdrengh M, Stossel TP, Tarkowski A, Maria Bokarewa M. Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10: R117.
18.
Watek M, Durnaś B, Wollny T, Pasiarski M, Góźdź S, Marzec M, Chabowska A, Wolak P, Żendzian-Piotrowska M, Bucki R. Unexpected profile of sphingolipid contents in blood and bone marrow plasma collected from patients diagnosed with acute myeloid leukemia. Lipids Health Dis 2017; 16: 235.
19.
Gay F, Estornes Y, Saurin JC, Joly-Pharaboz MO, Friederich E, Scoazec JY, Abello J. In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma. Hum Pathol 2008; 39: 1420-1430.
20.
Kuzumaki N, Tanaka M, Sakai N, Fujita H. Tumor suppressive function of gelsolin. Gan To Kagaku Ryoho 1997; 24: 1436-1441.
21.
Bucki R, Pastore JJ. Bacterial endotoxin as inhibitor of the enzymatic activity of human thrombin. Eur J Haematol 2006; 76: 510-515.
22.
Bucki R, Georges PC, Espinassous Q, Funaki M, Pastore JJ, Richard Chaby R, Paul A Janmey. Inactivation of endotoxin by human plasma gelsolin. Biochemistry 2005; 44: 9590-9597.
23.
Bucki R, Janmey PA, Interaction of the gelsolin-derived antibacterial PBP 10 peptide with lipid bilayers and cell membranes. Antimicrob Agents Chemother 2006; 50: 2932-2940.
24.
Bucki R, Durnaś B, Wątek M, Piktel E, Cruz K, Wolak P, Savage PB, Janmey PA. Targeting polyelectrolyte networks in purulent body fluids to modulate bactericidal properties of some antibiotics. Infect Drug Resist 2018; 11: 77-86.
25.
Huang LF, Yao YM, Li JF, Dong N, Liu C, Yu Y, He LX, Sheng ZY. Reduction of plasma gelsolin levels correlates with development of multiple organ dysfunction syndrome and fatal outcome in burn patients. PLoS One 2011; 6: e25748.
26.
DiNubile MJ, Levinson SL, Stossel TP, Lawrenz MB, Warawa JM. Recombinant human plasma gelsolin improves survival and attenuates lung injury in a murine model of multidrug-resistant pseudomonas aeruginosa pneumonia. Open Forum Infect Dis 2020; 7: ofaa236.
27.
Eaton SL, Hurtado ML, Oldknow KJ, Graham LC, Marchant TW, Gillingwater TH, Farquharson C, Wishart TM. A guide to modern quantitative fluorescent western blotting with troubleshooting strategies. J Vis Exp 2014; 93: e52099.
28.
Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996; 4: 430-435.
29.
Namendys-Silva SA, González-Herrera MO, Texcocano- Becerra J, Herrera-Gómez A. Clinical characteristics and outcomes of critically ill cancer patients with septic shock. QJM 2011; 104: 505-511.
30.
Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014; 2014: 149185.
31.
Watek M, Wnorowska U, Wollny T, Durnaś B, Wolak P, Kościołek-Zgódka S, Pasiarski M, Góźdź S, Bucki R. Hypogelsolinemia in patients diagnosed with acute myeloid leukemia at initial stage of sepsis. Med Sci Monit 2019; 25: 1452-1458.
32.
Dahl B, Schiødt FV, Ott P, Gvozdenovic R, Yin HL, Lee WM. Plasma gelsolin is reduced in trauma patients. Shock 1999; 12: 102-104.
33.
Mounzer KC, Moncure M, Smith YR, Dinubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med 1999; 160: 1673-1681.
34.
Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med 1997; 25: 594-598.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
